Business Wire

Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market

Share

Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London

Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/

null

Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire)

“Justin has been an integral member of our team over the last 17 years, contributing to significant growth at Cabot at a key societal inflection point – the growth of the ecommerce sector – which spurred robust demand for high-quality, well-located industrial assets on a global basis,” said Franz Colloredo-Mansfeld, Chairman and CEO of Cabot Properties. “As we recognized the opportunity to expand our investment activity outside the U.S. over a decade ago, he took on the challenging mandate to lead our investment activity and has generated impressive results to date. We’ve since grown our presence in Europe with teams located in the U.K., the Netherlands, and Germany. With Justin in London, the team in Europe is even better positioned to expand our investment activity.”

Cabot has acquired more than 970,000 square meters of logistics properties in Europe and the U.K. since 2011, adding nearly 300,000 square meters to its portfolio in the last two years alone. The company has been active in the German market since 2019 and opened a Munich office in 2024 to support its continued local portfolio growth.

“We see strong opportunity and positive demand tailwinds in the European logistics market, making this a critical moment to expand our team and focus across the region,” said Harvey. “Germany has one of the largest and most important logistics markets in Europe, and Thomas’ depth of knowledge, experience and relationships will give us an excellent advantage for growth in that market. This will help enable our European team to effectively execute a targeted management strategy that we believe will provide long-term value for our investors.”

Schellhorn joins Cabot following four years at Catella Real Estate AG, where he served as a Senior Asset Manager overseeing logistics properties and advising on acquisition and sustainability assessments. His experience in the German logistics real estate space has also spanned several leadership roles at reputable logistics and facility management firms including RLI Investors GmbH, Prologis Germany, DIW Instandhaltung Ltd., and the HOCHTIEF Group. Schellhorn studied facility management at the University of Applied Sciences Kufstein in Austria, graduating as a Qualified Engineer. He is also a Chartered Facility Management Surveyor with the Royal Institution of Chartered Surveyors (RICS).

Harvey has been with Cabot since 2008, having served in various leadership positions throughout the firm’s investment and finance teams prior to taking on his current role in overseeing the firm’s investment activity in Europe. Prior to joining Cabot, Harvey worked at FLAG Capital Management. He holds a Bachelor of Arts from Colby College and a Master of Business Administration from Dartmouth’s Tuck School of Business.

About Cabot Properties

Cabot Properties is an international private equity real estate firm focused on the logistics sector. Founded in 1986, Cabot was one of the first real estate firms to provide institutional investors with access to the industrial property sector and has invested over $15 billion in logistics real estate, served over 4,200 tenants, and operated over 1,600 buildings totaling more than 230 million square feet. Cabot is headquartered in Boston with offices in Atlanta, Chicago, Dallas, Los Angeles, London, Amsterdam, Sydney, Tokyo, and Munich. For more information, visit www.cabotprop.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114998320/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release

Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye